Lumos Diagnostics Embarks on Key FebriDx Study

Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.

Lumos Diagnostics has initiated a pivotal study in the U.S. to secure CLIA waiver status for its FebriDx test, which could significantly expand its market reach. Supported by BARDA’s funding, the study aims to improve antibiotic use by distinguishing bacterial infections, potentially unlocking a $1.7 billion market opportunity. Successful completion is anticipated by spring 2025, opening doors to a broader healthcare market.

For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.